NewTech.eu · 12 Nov 2026 · Collaborations & pilots
Biomatter raises USD 18 million; AstraZeneca, BASF, Sanofi and Tereos buy its AI-designed enzymes
AI enzyme-design startup Biomatter raised an USD 18 million Series A led by Astanor. It has built custom enzymes for AstraZeneca, BASF, Sanofi and Tereos, and a commercial product uses an enzyme it developed with Thermo Fisher Scientific. The money funds a design and testing facility in Vilnius opening in 2027.
Why it matters: Custom enzymes now take weeks instead of months; R&D teams in pharma, chemicals and food can test such suppliers on a single reaction first.
AstraZeneca+ FollowBASF+ FollowSanofi+ FollowTereos+ FollowThermo Fisher Scientific+ FollowBiotechAI & machine learning